Preclinical Research: Promising and Extensive

The body of preclinical evidence linking EGCG to cancer prevention is substantial. Laboratory studies — including cell culture experiments and animal models — have demonstrated EGCG's ability to:

• Inhibit proliferation of cancer cells across multiple cancer types (breast, prostate, colorectal, lung, skin)

• Induce apoptosis through both mitochondrial and death-receptor pathways

• Suppress angiogenesis (the formation of new blood vessels that tumors need to grow)

• Inhibit metastasis by reducing matrix metalloproteinase (MMP) activity

• Enhance the effectiveness of certain chemotherapy agents while reducing their side effects

A 2020 review published in the journal Molecules analyzed over 140 studies on EGCG's anticancer properties and concluded that it "targets multiple signaling pathways involved in cancer cell survival, proliferation, and invasion."

Human Clinical Studies: Encouraging but Cautious

Human clinical data is more limited than preclinical findings, but several large-scale epidemiological studies have shown meaningful associations:

• A Japanese cohort study of 40,530 adults found that those consuming 5 or more cups of green tea daily had a significantly lower risk of breast cancer recurrence compared to those consuming fewer cups.

• A meta-analysis of 51 observational studies (published in Biomedicine & Pharmacotherapy, 2020) found that green tea consumption was associated with a reduced risk of several cancer types, with the strongest evidence for liver, breast, and prostate cancers.

• A randomized controlled trial in men with prostate intraepithelial neoplasia (a precancerous condition) showed that EGCG supplementation (600mg/day) significantly reduced the progression to prostate cancer over one year.

It's important to note that most researchers emphasize EGCG as a preventive compound rather than a treatment. The doses used in clinical cancer studies typically range from 400-800mg per day, often from standardized green tea extracts rather than dietary intake alone.

Key Limitations to Understand

• Bioavailability of EGCG is relatively low — only about 0.1-5% is absorbed in the intestines without enhancement

• Taking EGCG with vitamin C or piperine may improve absorption

• Most clinical evidence shows association, not direct causation

• Extremely high doses (>800mg/day from supplements) have been linked to liver toxicity in rare cases